Health Canada has authorized the first generic versions of the active ingredient in Ozempic. Here’s what that means and how generics work.
For the first time anywhere in the G7, generic semaglutide is available. Health Canada has authorized two generic versions of the injectable medication — the same active ingredient found in Novo Nordisk’s brand-name Ozempic — and Canadian pharmacies now have access to both.
The approvals came after Novo Nordisk’s data exclusivity in Canada expired on January 4, 2026. Health Canada authorized Dr. Reddy’s Laboratories’ generic semaglutide injection on April 28, 2026, and Apotex’s Apo-Semaglutide Injection on May 1, 2026. Both began shipping to Canadian pharmacies in mid-May.
What “generic” actually means
A generic medication contains the same active ingredient, at the same strength, in the same dosage form as its brand-name counterpart. Before a generic can be sold in Canada, Health Canada conducts a full scientific review covering safety, efficacy, and manufacturing quality. A core part of that review is bioequivalence — proving that the generic delivers the same amount of active ingredient into the bloodstream, at the same rate, as the brand.
In this case, Health Canada reviewed both products as generic versions of Ozempic and confirmed they meet its standards. Each carries its own Drug Identification Number (DIN) and is regulated under the same Good Manufacturing Practices framework as the brand.
The two generics now authorized
Dr. Reddy’s Laboratories Semaglutide Injection. Dr. Reddy’s became the first company in any G7 country to receive marketing authorization for generic semaglutide. The active pharmaceutical ingredient is produced in-house by Dr. Reddy’s, a global pharmaceutical manufacturer with more than 40 years of regulatory experience across Canada, the U.S., the U.K., and the EU.
Apotex Apo-Semaglutide Injection. Apotex is Canada’s largest generic pharmaceutical company, headquartered in Toronto with Canadian manufacturing operations. Apo-Semaglutide is the first Canadian-made generic equivalent of Ozempic.
Both products are supplied as sterile pre-filled pens at the same strengths as brand-name Ozempic — 2 mg/pen (delivering 0.25 mg or 0.5 mg doses) and 4 mg/pen (delivering 1 mg doses) — so the dose titration schedule does not change when switching between brand and generic.
Why this matters globally
Canada is the first G7 country to authorize a generic semaglutide. Novo Nordisk’s foundational Canadian patent for the molecule lapsed in 2020 after a missed maintenance fee, and the eight-year regulatory data exclusivity window expired this past January. In other major markets, including the United States and most of Europe, brand exclusivity remains in place — projections place a U.S. generic approval years away.
Canada’s regulatory pathway also moved relatively quickly. Health Canada’s review target for generic submissions is 180 days, shorter than many international regulators, and Dr. Reddy’s application was completed inside that window.
What about Rybelsus and Wegovy?
Rybelsus is the oral tablet form of semaglutide, and Wegovy is the higher-dose injectable form approved for chronic weight management — both manufactured by Novo Nordisk. The generic approvals issued so far cover the injectable form indicated for type 2 diabetes only. Generics of Rybelsus and Wegovy are not yet available; the brand-name versions remain the only options for those indications.
The Canadian pharmaceutical supply chain
Every prescription drug dispensed by a Canadian pharmacy — brand or generic — moves through several layers of oversight: Health Canada authorization at the federal level, provincial pharmacy regulatory colleges that license and inspect pharmacies, wholesalers operating under federal Drug Establishment Licences, and pharmacist verification at the point of dispensing. Generic manufacturers are subject to the same Good Manufacturing Practices inspections as brand manufacturers, including on-site audits of production facilities both domestically and internationally.
For anyone currently taking brand-name Ozempic, the introduction of generic options doesn’t change the molecule, the dose, the device, or the schedule — only the manufacturer and, typically, the cost. The decision to switch is one to discuss with a prescriber, who can assess whether a generic substitution is appropriate for any individual case.
For inquiries about prescription medications, contact our team at Jason’s CanadaDrugstore.com by calling 1-800-226 3784 (CAN-DRUG) for assistance from our patient representatives or a licensed Canadian pharmacist.
This article provides medical information to help understand a condition or treatment plan but is not a diagnosis or treatment recommendation. Contact your doctor if you have concerns or symptoms. In case of emergency, call 911.
Leave a Reply